# GEO earnings call intelligence LOPJLB CallCard / temporal rollup · freemium · [stock page](https://www.lopjlb.com/stock/GEO) · [Earnings tab](https://www.lopjlb.com/stock/GEO?tab=earnings) Updated: 2026-10-03T05:59:45 Quarters analyzed: 8 ## Cross-quarter narrative Across 8 calls for GEO, management tone moved from +0.50 (2024 Q3) to +0.70 (2026 Q2). Latest guidance stance: raised. Latest desk line: GEO Group Q2 2026 revenue up 15% and net income up 63%, driven by new ICE contracts and facility activations, prompting raised full‑year guidance and continued share repurchases. ## Latest CallCard · Q2 GEO Group Q2 2026 revenue up 15% and net income up 63%, driven by new ICE contracts and facility activations, prompting raised full‑year guidance and continued share repurchases. **Guidance:** raised — Management raised full‑year net income and adjusted EBITDA guidance reflecting strong Q2 performance. **Tone:** mgmt 0.7 · Q&A pressure 0.4 · divergence 0.3 Prepared remarks highlighted strong revenue growth, new contracts and raised guidance, showing optimism. ### Demand visibility Strong ICE demand and potential for additional beds. ICE populations rose 20% in six weeks; active ICE beds now ~27,000 with up to 4.5k idle beds that could add ~$250M revenue if reactivated. ### Margins / costs Margins pressured by activation costs but offset by labor savings and lower interest expense. Operating expenses rose ~12% due to facility activations, yet labor cost savings helped; net interest expense fell $4M as debt was reduced. ### Capital allocation Ongoing share repurchases and plan to use proceeds from asset sales for debt reduction and buybacks. Repurchased 1.6M shares for $37M in Q2, total $177M since program start; $323M remaining authorization. Post‑sale proceeds will target debt repayment and additional buybacks. ### Milestones - **Bighorn facility activation** [on_track]: 5‑year support services contract expected completed by end 2026, normalized earnings early 2027. - **Rivers facility activation** [on_track]: 5‑year support services contract expected completed by end 2026, normalized earnings early 2027. - **New ICE contracts for 4 facilities** [on_track]: ~$280M annual revenue, ~6,000 beds, increasing total active ICE beds to ~27,000. - **ISAP‑V technology shift** [on_track]: Ankle monitor participants up to 54k, driving higher revenue mix. - **Skip tracing contract ramp‑up** [at_risk]: No Q2 revenue due to ICE funding lapse; expects ramp in H2 2026. - **Potential sale of 4 facilities** [at_risk]: Procurement process aims to complete by end of quarter, could spill into next quarter. - **Graceville and Bay facility contracts** [new]: Rescheduled to transition to GEO on 07/01/2027, $100M combined annual revenue. - **Share repurchase program** [on_track]: Repurchased 1.6M shares for $37M in Q2; $323M remaining authorization. ### Fears / risks - **Funding risk**: ICE appropriations lapse caused skip‑tracing revenue loss in Q2. - **Contract execution risk**: Activation of Bighorn and Rivers facilities depends on capital reimbursement and could face delays. - **Regulatory risk**: Changes in ICE immigration enforcement policy could affect detainee populations and contract volumes. - **Revenue concentration**: Heavy reliance on ICE contracts makes GEO vulnerable to policy or funding changes. - **Debt covenant risk**: Debt agreements restrict use of proceeds from asset sales, limiting flexibility. - **Technology cost risk**: Shift from SmartLink app to ankle monitors may increase costs if volume rises. - **Market demand volatility**: ICE population increased 20% recently but could fluctuate. - **Geographic cost risk**: Facility activation costs vary by location, affecting profitability. ### Key quotes > “Revenues increased 15% from the second quarter of 2 thousand 25, while net income increased 63% from the same period.” > “We entered into new contracts to house ICE detainees at 4 facilities valued at approximately $280 million in annual revenues and totaling approximately 6 thousand beds.” > “We do expect to receive another contract this quarter. Possibly this month. And I think that number you quoted is correct.” — George C. Zoley > “No. I believe ICE has maybe $36 billion left for the buildup and of new facilities. And I believe that money is allocated through the president's current term.” — George C. Zoley ## Quarter one-liners - **2026 Q2:** GEO Group Q2 2026 revenue up 15% and net income up 63%, driven by new ICE contracts and facility activations, prompting raised full‑year guidance and continued share repurchases. - **2026 Q1:** GEO Group raised its 2026 outlook, citing new ICE contracts, idle‑bed upside and ISAP growth, while noting payment delays from a DHS shutdown and uncertainty on facility utilization. - **2025 Q4:** — - **2025 Q3:** GEO reported solid Q3 earnings, new ICE contracts and facility activations driving revenue growth, reduced debt and a stock buyback, but highlighted margin pressure and uncertainty around contract timing due to a government shutdown and policy reviews. - **2025 Q2:** GEO Q2 2025: Activated 4 ICE facilities ($240M annualized), sold Lawton for $312M, bought San Diego facility, extended revolver to $450M, guiding stable ISAP, optimistic on ICE expansion to 100k beds funded by $171B reconciliation bill. - **2025 Q1:** GEO Group Q1 2025: Updated guidance reflects higher first-half costs for growth positioning; new ICE contracts at Delaney Hall and Northlake add 2,800 beds; $800M-$1B annualized revenue upside identified contingent on congressional funding and ISAP extension. - **2024 Q4:** GEO Group Q4 2024 earnings showed higher overhead and lower earnings, but management highlighted upcoming ICE bed expansions, GPS production, transport fleet upgrades and a new 15‑year ICE contract, while noting funding and contract timing uncertainties. - **2024 Q3:** Q3 2024 revenue fell short due to lower Electronic Monitoring earnings, ICE bed utilization held steady, debt reduced $92M and guidance for Q4 was kept consistent while management highlights growth potential from idle beds and upcoming contracts. ## Theme arcs - **Management tone** (improving): Δ mgmt=+0.20 ## Fear persistence - **funding uncertainty** [recurring]: 2024 Q3, 2025 Q1, 2025 Q2 - **contract extension risk** [resolved]: 2024 Q3 - **political risk** [resolved]: 2024 Q3 - **utilization risk** [resolved]: 2024 Q3 - **debt level** [recurring]: 2024 Q3, 2024 Q4 - **funding risk** [recurring]: 2024 Q4, 2026 Q2 - **legislative risk** [resolved]: 2024 Q4 - **contract award uncertainty** [resolved]: 2024 Q4 - **operational staffing risk** [resolved]: 2024 Q4 - **sale execution risk** [resolved]: 2024 Q4 ## Guidance path 2024 Q3:maintained → 2024 Q4:maintained → 2025 Q1:maintained → 2025 Q2:maintained → 2025 Q3:vague → 2025 Q4:vague → 2026 Q1:raised → 2026 Q2:raised --- Research context only. Not personalized investment advice. API: `GET /bff/api/bigfive/earnings-intel/GEO`